Patents by Inventor Kim Folger Bruce

Kim Folger Bruce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Random transposon insertion in and use thereof to identify essential genes
    Patent number: 8173363
    Abstract: The invention provides a method for generating a database of candidate essential genes in Staphylococcus aureus, as well as otherwise important genes that, when mutated, lead to a growth attenuated phenotype. Such genes and mutants of such genes are important for identifying antibacterial agents suitable for treating and preventing S. aureus infections. The invention includes methods for confirming the essentiality or importance of candidate genes, as well as methods for utilizing those genes to screen for new antibacterial drugs. The invention also includes the antibacterial agents identified using the disclosed methods, as well as methods of using the same for treating and preventing Staphylococcus infection.
    Type: Grant
    Filed: August 20, 2003
    Date of Patent: May 8, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Kim Folger Bruce, Paul Warrener, Jennifer McLarnan, Kevin Hou
  • Essential and important genes of and the use thereof to design or identify antibacterial agents
    Patent number: 7629141
    Abstract: The invention includes a database of candidate essential genes in Pseudomonas aeruginosa, as well as other important genes that, when mutated, lead to a growth attenuated phenotype. Such genes and mutants of such genes are important for identifying antibacterial agents suitable for treating and preventing Pseudomonas aeruginosa infections. The invention includes methods for confirming the essentiality or importance of candidate genes, as well as methods for utilizing those genes to screen for new antibacterial drugs. The invention also includes the antibacterial agents identified using the disclosed methods, as well as methods of using the same for treating and preventing Pseudomonas infection.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: December 8, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Kim Folger Bruce, Paul Warrener, Kevin Hou
  • Novel antibodies reactive with human carcinomas
    Publication number: 20040043029
    Abstract: The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab′)2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab′)2-LysPE40 and ChiBR96 Fab′-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity.
    Type: Application
    Filed: January 2, 2003
    Publication date: March 4, 2004
    Applicant: Bristol-Myers Squibb Company
    Inventors: Ingegerg Hellstrom, Karl Erik Hellstrom, Kim Folger Bruce, George J. Schreiber
  • Novel antibody conjugates reactive with human carcinomas
    Publication number: 20020192223
    Abstract: The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab′)2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab′)2-LysPE40 and ChiBR96 Fab′-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity.
    Type: Application
    Filed: February 12, 2001
    Publication date: December 19, 2002
    Inventors: Ingegerg Hellstrom, Karl Erik Hellstrom, Kim Folger Bruce, George J. Schreiber
  • Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
    Patent number: 6020145
    Abstract: The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab').sub.2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab').sub.2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity.
    Type: Grant
    Filed: November 3, 1994
    Date of Patent: February 1, 2000
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ingegerd Hellstrom, Karl Erik Hellstrom, Kim Folger Bruce, George J. Schreiber
  • Antibodies reactive with human carcinomas
    Patent number: 5980896
    Abstract: The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab').sub.2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab').sub.2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity.
    Type: Grant
    Filed: June 14, 1993
    Date of Patent: November 9, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ingegerd Hellstrom, Karl Erik Hellstrom, Kim Folger Bruce, George J. Schreiber, Clay Siegall, Stephen McAndrew
  • Antibody conjugates reactive with human carcinomas
    Patent number: 5869045
    Abstract: The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab').sub.2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab').sub.2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: February 9, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ingegerg Hellstrom, Karl Erik Hellstrom, Kim Folger Bruce, George J. Schreiber